Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia 19Leukemia, Myelomonocytic, Acute 11Leukemia, Monocytic, Acute 10Leukemia, Erythroblastic, Acute 9Congenital Abnormalities 8Leukemia, Megakaryoblastic, Acute 7Burkitt Lymphoma 6Myelodysplastic Syndromes 4Leukemia, Eosinophilic, Acute 4Myeloproliferative Disorders 3Lymphoma 3Leukemia, Biphenotypic, Acute 3Leukemia, Basophilic, Acute 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Hematologic Neoplasms 2Thrombocytopenia 1Thrombocythemia, Essential 1Sarcoma, Myeloid 1Primary Myelofibrosis 1Polycythemia Vera 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunoproliferative Disorders 1

Interventions

Tretinoin 5Methotrexate 5Tacrolimus 4Arsenic Trioxide 4fludarabine phosphate 3Peripheral Blood Stem Cell Transplantation 3Busulfan 3Mycophenolic Acid 2Mercaptopurine 2Idarubicin 2Gemtuzumab 2Filgrastim 2Cytarabine 2Cyclophosphamide 2Antilymphocyte Serum 2thymoglobulin 1entinostat 1Whole-Body Irradiation 1Vorinostat 1Sorafenib 1Sirolimus 1Granulocyte Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Daunorubicin 1Clofarabine 1Bortezomib 1Biopsy 1Azacitidine 1Alemtuzumab 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Promyelocytic, Acute × Daunorubicin × Clear all
NCT01253070 2022-08-04

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
54 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡